The authors analyzed 410 cancer genes on kidney tumor samples of 524 patients through an MSK-IMPACT gene panel. Patients with ELOC mutations were identified, separated, and had their medical records reviewed. Two genitourinary pathologists immunohistochemically stained and pathologically evaluated the tissue samples. He additionally stated that ELOC-mutant RCC has distinct pathological features that can usually signify an indolent tumor.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
In conclusion, Dr. DiNatale and team realized that ELOC-mutant RCCs are not necessarily indolent and that metastatic tumors show evolutionary trajectories of higher complexity. An audience member questioned how Mitchell et al. determined the evolutionary history and how that study could be used to infer the same timeline for ELOC-mutant RCC. Dr. Natale stated that clear cell RCC was very similar to ELOC-mutant RCC and thus could then be used to assume an analogous evolutionary history.
Presented by: Renzo DiNatale, MD
Written by: Vinay Cooper, Department of Urology, University of California-Irvine at the 2018 AUA Annual Meeting - May 18 - 21, 2018 – San Francisco, CA USA